Advertisement

Clinical Pharmacokinetics

, Volume 9, Issue 1, pp 42–66 | Cite as

Drug Therapy in Patients Undergoing Haemodialysis Clinical Pharmacokinetic Considerations

  • Ching-san C. Lee
  • Thomas C. Marbury
Review Article

Summary

Haemodialysis is utilised therapeutically as supportive treatment for end-stage renal disease (ESRD). In conjunction with haemodialysis therapy, ESRD patients frequently receive a large number of drugs to treat a multitude of intercurrent conditions. Because of the impaired renal function in ESRD patients, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs and active metabolites with extensive renal excretion. On the other hand, if the removal of a drug by haemodialysis during concomitant drug therapy is significant, a dosage supplement would be required to ensure adequate therapeutic efficacy. Knowledge of the impact of haemodialysis on the elimination of specific drugs is therefore essential to the rational design of the dosage regimen in patients’ undergoing haemodialysis.

This review addresses the clinical pharmacokinetic aspects of drug therapy in haemodialysis patients and considers: (a) the effects of ESRD on the general pharmacokinetics of drugs; (b) dialysis clearance and its impact on drug and metabolite elimination; (c) the definition of dialysability and the criteria for evaluation of drug dialysability; (d) pharmacokinetic parameters which are useful in the prediction of drug dialysability; and (e) the application of pharmacokinetic principles to the adjustment of dosage regimens in haemodialysis patients. Finally, drugs commonly associated with haemodialysis therapy are tabulated with updated pharmacokinetics and dialysability information.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler, D.S.; Martin, E.; Gambertoglio, J.G.; Tozer, T.N. and Spire, J.P.: Hemodialysis of phenytoin in a urémie patient. Clinical Pharmacology and Therapeutics 18: 65–69 (1975).PubMedGoogle Scholar
  2. Alleta, J.M.; Franke, E.F. and Neu, H.C.: Intravenous azlocillin kinetics in patients on long-term hemodialysis. Clinical Pharmacology and Therapeutics 27: 563–566 (1980).CrossRefGoogle Scholar
  3. Amdisen, A. and Skjoldborg, H.: Haemodialysis for lithium poisoning. Lancet 2: 213 (1969).PubMedCrossRefGoogle Scholar
  4. Andreasen, F.: Protein binding of drugs in serum from patients with acute anuria. Acta Pharmacologica et Toxicologica 29 (Suppl. 4): 2 (1971).Google Scholar
  5. Anton. AH. and Corey, W.T.: lnterindividual differences in the protein binding of sulfonamides: The effects of disease and drugs. Acta Pharmacologica et Toxicologica 29 (Suppl. 3): 134–151 (1971).PubMedGoogle Scholar
  6. Aronoff, G.R.; Szwed, J.J.; Nelson, R.L.; Marcus, E.L. and Kleit, S.A.: Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrobial Agents and Chemotherapy 18: 212–214 (1980).PubMedCrossRefGoogle Scholar
  7. Avram, M.M. and McGinn, J.T.: Extracorporeal hemodialysis in phenothiazine overdose. Journal of the American Medical Association 197: 142–143 (1966).PubMedCrossRefGoogle Scholar
  8. Bailey, R.R.; Gower, P.E. and Dash, C.H.: The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. Postgrad. M. J. 46 (Suppl.): 60–64 (1970).Google Scholar
  9. Bailey, R.R.; Sharman, J.R.; O’Rourke, J. and Buttimore, A.L.: Hemodialysis and forced diuresis for tricyclic antidepressant poisoning. British Medical Journal 4: 230–231 (1974).PubMedCrossRefGoogle Scholar
  10. Balogh, A.; Funfstuck, R.; Kangas, L.; Demme, U.; Sperschneider, H.; Traeger, A.; Stein, G. and Pekkarinen, A.: Comparative in vitro investigations on the dialyzability of hypnotic and psychotropic drugs by hemodialysis and controlled sequential ultradiffusion. Archives of Toxicology 4 (Suppl.): 335–337 (1980).PubMedCrossRefGoogle Scholar
  11. Bauer, L.A.; Raisys, V.A.; Watts, M.T. and Ballinger, J.: The pharmacokinetics of thiobendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfu-sion. Journal of Clinical Pharmacology 22: 276–280 (1982).PubMedGoogle Scholar
  12. Berman, S.; Boughton, W.; Sugihara, J.; Wong, E.; Sato, M. and Siemsen, A.: Pharmacokinetics of cefaclor in patients with end-stage renal disease and during hemodialysis. Antimicrobial Agents and Chemotherapy 14: 281–283 (1978).PubMedCrossRefGoogle Scholar
  13. Bennett, W.M.; Bagby, S.P.; Golper, T.A. and Porter, G.A.: Vancomycin therapy for difficult infections in hemodialysis patients. Dialysis and Transplantation 6: 22–25 (1977).Google Scholar
  14. Bennett, W.M.; Muther, R.S.; Parker, R.A.; Feig, P.; Morrison, G.; Golper, J.A. and Singer, I.: Drug therapy in renal failure: Dosing guidelines for adults. Annals of Internal Medicine 93: 62–89, 286–325 (1980).PubMedGoogle Scholar
  15. Bianchetti, G.; Grazini, G. and Brancaccio, D.: Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clinical Pharmacokinetics 1: 373–384 (1976).PubMedCrossRefGoogle Scholar
  16. Bickel, M.H.: Poisoning by tricyclic antidepressant drugs: General and pharmacokinetic considerations. International Journal of Clinical Pharmacology and Biopharmacy 11: 145–176 (1975).PubMedGoogle Scholar
  17. Block, E.R.; Bennett, J.E.; Liovoti, L.G.; Klein, W.J.; Jr.; MacGregor, R.R. and Henderson, L.: Flucytosine and amphotericin, B: hemodialysis effects on the plasma concentration and clearance: studies in man. Annals of Internal Medicine 80: 613–617 (1974).PubMedGoogle Scholar
  18. Bowersox, D.W.; Winterbauer, R.H.; Stewart, G.L.; Orme, B. and Barson, R.: Isoniazid dosage in patients with renal failure. New England Journal of Medicine 289: 84–87 (1973).PubMedCrossRefGoogle Scholar
  19. Bruni, J.; Wang, L.H.; Marbury, T.C.; Lee, C.S. and Wilder, B.J.: Protein binding of valproic acid in uremic patients. Neurology 30: 557–559 (1980).PubMedCrossRefGoogle Scholar
  20. Bryan, C.S. and Stone, W.J.: “Comparably massive” penicillin G therapy in renal failure. Annals of Internal Medicine 82: 189–195 (1975).PubMedGoogle Scholar
  21. Christopher, T.G.; Korn, N.; Blair, A.D.; Forrey, A.W.; O’Neil, M.A. and Cutler, R.E.: Gentamycin kinetics during hemodialysis. Kidney International 6: 38–44 (1974).PubMedCrossRefGoogle Scholar
  22. Cimino, J.E. and Tierno, P.M.; Jr.: Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Applied Microbiology 17: 446–448 (1969).PubMedGoogle Scholar
  23. Collinsworth, K.A.; Stong, J.M.; Atkinson, A.J.; Winkle, R.A.; Perlroth, F. and Harrison, D.C.: Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clinical Pharmacology and Therapeutics 18: 59–64 (1975).PubMedGoogle Scholar
  24. Craig, C.P. and Rifkin, S.I.: Pharmacokinetics and hemodialyzability of cefazolin in uremic patients. Clinical Pharmacology and Therapeutics 19: 825–829 (1976).PubMedGoogle Scholar
  25. Cruz, I.A.; Cramer, N.C. and Parrish, A.E.: Hemodialysis in chlordiazepoxide toxicity. Journal of the American Medical Association 202: 438–440 (1967).PubMedCrossRefGoogle Scholar
  26. Cunha, B.A.; Quintiliani, R.; Deglin, J.M.; Izard, M.W. and Nightingale, C.H.: Pharmacokinetics of vancomycin in anuria. Reviews of Infectious Diseases 3 (Suppl.): S269–272 (1981).PubMedGoogle Scholar
  27. Curry, S.H.; Riddall, D.; Gordon, J.S.; Simpson, P.; Bins, T.B.; Rondel, R.K. and McMartin, C: Disposition of glutethimide in man. Clinical Pharmacology and Therapeutics 12: 849–875 (1972).Google Scholar
  28. Cutler, R.; Blair, A. and Kelly, M.: Flucytosine kinetics in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics 24: 333–342 (1978).PubMedGoogle Scholar
  29. Czcrwinski, A.W. and Pederson, J.A.: The pharmacology of cefa-mandole in patients with reduced renal function. Scandinavian Journal of Infectious Diseases 25 (Suppl.): 45–48 (1980).Google Scholar
  30. Danish, M.; Schultz, R. and Jusko, W.J.: Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrobial Agents and Chemotherapy 6: 841–847 (1974).PubMedCrossRefGoogle Scholar
  31. Dawling, S.; Lynn, K.; Rosser, R. and Braithwaite, R.: Nortrip-tyline metabolism in chronic renal failure: metabolite elimination. Clinical Pharmacology and Therapeutics 32: 322–329 (1982).PubMedCrossRefGoogle Scholar
  32. Dettli, L.: Drug usage in renal disease. Clinical Pharmacokinetics 1: 126–134 (1976).PubMedCrossRefGoogle Scholar
  33. Dromgoole, S.H.: The effect of hemodialysis on the binding capacity of albumin. Clinica Chimica Acta 46: 469–472 (1973).CrossRefGoogle Scholar
  34. Eastwood, J.B. and Curtis, J.R.: Carbenicillin administration in patients with severe renal failure. British Medical Journal 1: 486–487 (1968).PubMedCrossRefGoogle Scholar
  35. Farid, N.R.; Glynn, J.P. and Kerr, D.N.S.: Haemodialysis in paracetamol selfpoisoning. Lancet 2: 396–398 (1972).PubMedCrossRefGoogle Scholar
  36. Farrcl, P.C.; Grib, N.L.; Fry, D.L.; Popovich, R.P.; Broviac, J.W. and Babb, A.L.: A comparison of in vitro and in vivo soluteprotein binding interactions in normal and uremic subjects. Transactions of the American Society for Artificial Internal Organs 18: 268–276 (1972).CrossRefGoogle Scholar
  37. Faulkner, R.D.; Senekjian, H.O. and Lee, C.S.: Hemodialysis of doxcpin and desmethyldoxepin in uremic patients. International Journal of Artificial Organs (In press, 1983).Google Scholar
  38. Floyd, M.; Hill, A.V.L.; Ormston, B.J.; Menzies, R. and Porter, R.: Quinine amblyopia treated by hemodialysis. Clinical Ne-phrology 2: 44–46 (1974).Google Scholar
  39. Francke, E.; Appel, G.B. and Neu, H.C.: Kinetics of intravenous amoxcillin in patients on long term dialysis. Clinical Pharmacology and Therapeutics 26: 31–35 (1979).PubMedGoogle Scholar
  40. Frey, F.J.; Gambertoglio, J.G.; Frey, B.M.; Benet, L.Z. and Amend, W.J.: Nonlinear plasma protein binding and hemodialysis clearance of prednisolone. European Journal of Clinical Pharmacology 23: 65–74 (1982).PubMedCrossRefGoogle Scholar
  41. Gabriel, R.; Page, C.M.; Collier, J.; Houghton, G.W.; Templeton, R. and Thome, P.S.: Removal of metronidazole by hemodialysis. British Journal of Surgery 67: 553 (1980).PubMedCrossRefGoogle Scholar
  42. Gambertoglio, J.G.: Pharmacokinetic principles and renal disease. Dialysis and Transplantation 8: 8–23 (1979).Google Scholar
  43. Gibson, T.P.: Dialyzability of common therapeutic agents. Dialysis and Transplantation 8: 24–40 (1979).Google Scholar
  44. Gibson, P.F. and Wright, N.: Ethchlorvynol in biological fluids: specificity of assay methods. Journal of Pharmaceutical Sciences 61: 169–171 (1972).PubMedCrossRefGoogle Scholar
  45. Gibson, T.P.; Matusik, E.; Nelson, L.D. and Biggs, W.A.: Artificial kidneys and clearance calculations. Clinical Pharmacology and Therapeutics 20: 720–726 (1976).PubMedGoogle Scholar
  46. Gibson, T.P.; Atkinson, A.J.; Matusik, E.; Nelson, L.D. and Biggs, W.A.: Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney International 12: 422–429 (1977).PubMedCrossRefGoogle Scholar
  47. Gibson, T.P.; Granneman, G.R.; Kallal, J.E. and Sennello, L.T.: Ccfsulodin kinetics in renal impairment. Clinical Pharmacology and Therapeutics 31: 602–608 (1982).PubMedCrossRefGoogle Scholar
  48. Goetz, DR.; Pancorbo, S.; Hoag, S. and Bloom, P.: Prediction of serum gentamycin concentrations in patients undergoing hemodialysis. American Journal of Hospital Pharmacy 37: 1077–1083 (1980).PubMedGoogle Scholar
  49. Gold, C.H.; Buchanan, N.; Tingham, V.; Viljoen, M.; Strickwold, B. and Moodley, G.P.: Isoniazid pharmacokinetics in patients with chronic renal failure. Clinical Nephrology 6: 365–369 (1976).PubMedGoogle Scholar
  50. Goodwin, N.J. and Friedman, E.A.: The effects of renal impairment, peritoneal dialysis and hemodialysis on serum sodium colistimethate levels. Annals of Internal Medicine 68: 984–994 (1968).PubMedGoogle Scholar
  51. Gwilt, P.R.: Assessing drug removal by extracorporeal dialysis. Journal of Pharmaceutical Sciences 70: 345 (1981).PubMedCrossRefGoogle Scholar
  52. Gwilt, P. and Perrier, D.: Plasma protein binding and distribution characteristics of drugs as indices of hemodialyzability. Clinical Pharmacology and Therapeutics 24: 154–161 (1978).PubMedGoogle Scholar
  53. Hallan, H.; Svarva, P.L.; Svartas, T.M. and Wideroe, T.: Azlo-cillin treatment of urinary tract infection in patients on hemodialysis. Scandinavian Journal of Infectious Diseases 29: 55–58 (1981).PubMedGoogle Scholar
  54. Halpren, B.A.; Avline, S.G.; Coplan, N.S. and Brown, D.M.: Clearance of gentamycin during hemodialysis: Comparison of four artificial kidneys. Journal of Infectious Diseases 133: 627–636 (1976).PubMedCrossRefGoogle Scholar
  55. Handc, K.R.; Balow, J.E.; Drake, J.C.; Rosenberg, S.A. and Chabncr, B.A.: Methotrexale and hemodialysis. Annals of Internal Medicine 87: 495–496 (1977).Google Scholar
  56. Hawkins, S.S.; Alford, R.H.; Stone, W.J.; Smyth, R.D. and Pfeffer, M.: Ceforanide kinetics in renal insufficiency. Clinical Pharmacology and Therapeutics 30: 468–474 (1981).PubMedCrossRefGoogle Scholar
  57. Henderson, L.W.: Symptomatic hypotension during hemodi-alysis. Kidney International 17: 571–576 (1980).PubMedCrossRefGoogle Scholar
  58. Henderson, L.W. and Merrill, J.P.: Treatment of barbiturate intoxication. Annals of Internal Medicine 64: 876–891 (1966).Google Scholar
  59. Henderson, R.G.; Wheatley, T.; English, J.; Chakraborty, J. and Marks, V.: Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisoione. British Medical Journal 1: 1534–1536 (1979).PubMedCrossRefGoogle Scholar
  60. Hervengt, C; Desager, J.P.; Muschart, J.M.; Tjandramaga, T.B.; Verbeeck, R. and Verberckmoes, R.: Influence of hemodialysis on the half-life of practolol in patients with severe renal failure. Journal of Clinical Pharmacology 15: 605–610 (1975).Google Scholar
  61. Hess, J.R.; Berman, S.J.; Boughton, W.H.; Sugihara, J.G.; Musgravc, J.E.; Wong, E.G.C. and Siemsen, A.M.: Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis. Antimicrobial Agents and Chemotherapy 17: 251–253 (1980).PubMedCrossRefGoogle Scholar
  62. Hoffman, T.A.; Cestero, R. and Bullock, W.E.: Pharmacodynamics of carbenicillin in hepatic and renal failure. Annals of Internal Medicine 73: 173–178 (1970).PubMedGoogle Scholar
  63. Horn, J.R. and Hughes, M.L.: Disopyramide dialysability. Lancet 2: 214 (1978).Google Scholar
  64. Howell, S.B.; Blair, H.E.; Uren, J. and Frei, E.: Hemodialysis and enzymatic cleavage of methotrexate in man. European Journal of Cancer 14: 787–792 (1978).PubMedCrossRefGoogle Scholar
  65. Hulter, H.N.; Licht, J.H.; Ilnicki, L.P. and Singh, S.: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency. Journal of Laboratory and Clinical Med icine 94: 223–231 (1979).Google Scholar
  66. Humbert, G.; Fillastre, J.P.; Leroy, A.; Godin, M. and Van Win-zum, C: Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Reviews of Infectious Diseases 1: 118–126 (1979a).PubMedCrossRefGoogle Scholar
  67. Humbert, G.; Leroy, A.; Fillastre, J. and Godin, M.: Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy 25: 189–195 (1979b).PubMedCrossRefGoogle Scholar
  68. Hurwitz, A.: Gastrointestinal Drug Absorption: Effects of Antacids. Morselli et al. (Eds) Drug Interactions, pp. 21–31 (Raven Press, New York 1974).Google Scholar
  69. Iisalo, E.: Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 2: 1–16 (1977).PubMedCrossRefGoogle Scholar
  70. Iliopoulou, A.; Downey, K.; Chaput de Saintonge, D.M. and Turner, P.: Should erythromycin dose be altered in hemodialysis patients. European Journal of Clinical Pharmacology 23: 435–440 (1982).PubMedCrossRefGoogle Scholar
  71. Ing, T.S.; Mahurkar, S.D.; Dunea, G.; Hayashi, J.A.; Klawans, H.L. and Markey, W.S.: Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency. Canadian Medical Association Journal 115: 515–516 (1976).PubMedGoogle Scholar
  72. Ings, R.M.; Fillastre, J.P.; Godin, M.; Leroy, A. and Humbert, G.: The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Review of Infectious Diseases 4: s379–391 (1982).Google Scholar
  73. Janicke, D.M.; Mangione, A.; Schultz, R.W. and Jusko, W.J.: Mezlocillin disposition in chronic hemodialysis patients. Antimicrobial Agents and Chemotherapy 20: 590–594 (1981).PubMedCrossRefGoogle Scholar
  74. Josselson, J.; Narang, P.K.; Adir, J.; Yacobi, A. and Sadler, J.H.: Bretylium kinetics in renal insufficiency. Clinical Pharmacology and Therapeutics 33: 144–150 (1983).PubMedCrossRefGoogle Scholar
  75. Jusko, W.J. and Weintraub, M.: Myocardial distribution of digoxin and renal function. Clinical Pharmacology and Therapeutics 16: 449–454 (1974).PubMedGoogle Scholar
  76. Jusko, W.J.; Lewis, G.P. and Schmitt, G.W.: Ampicillin and hetacillin pharmacokinetics in normal and anephric patients. Clinical Pharmacology and Therapeutics 14: 90–99 (1973).PubMedGoogle Scholar
  77. Karim, A.: Disopyramide dialyzability. Lancet 2: 214 (1978).CrossRefGoogle Scholar
  78. Kirch, W.; Kohler, H. and Axthelm, T.: Pharmacokinetics of guanfacine in patients undergoing hemodialysis. European Journal of Drug Metabolism and Pharmacokinetics 4: 277–280 (1982).CrossRefGoogle Scholar
  79. Knepshield, J.H.; Schreiner, G.E.; Lowenthal, D.T. and Gelfand, M.C.: Dialysis of poisons and drugs. Transactions of the American Society for Artificial Internal Organs 19: 590–633 (1973).PubMedCrossRefGoogle Scholar
  80. Koch-Weser, J.: Pharmacokinetics of procainamide in man. Annals of the New York Academy of Sciences 170: 370–382 (1971).CrossRefGoogle Scholar
  81. Kramer, P.: Digitalis pharmacokinetics and therapy with respect to impaired renal function. Klinische Wochenschrift 55: 1–11 (1977).PubMedCrossRefGoogle Scholar
  82. Kreeft, J.H.; Ogilvie, R.I. and Dufresne, L.R.: Metronidazole kinetics in dialysis patients. Surgery 93: 149–153 (1983).PubMedGoogle Scholar
  83. Krumlovsky, F.A.; Emmerman, J.; Parker, R.H.; Wisgerhof, M. and DelGreco, F.: Dialysis in treatment of neomycin over-dosage. Annals of Internal Medicine 76: 443–446 (1972).PubMedGoogle Scholar
  84. Laskin, O.L.; Longstreth, J.A.; Whelton, A.; Rocco, L.; Lietman, P.S.; Krasny, H.C. and Keeney, R.E.: Acyclovir kinetics in end-stage renal disease. Clinical Pharmacology and Therapeutics 31: 594–601 (1982).PubMedCrossRefGoogle Scholar
  85. Lee, C.S.: The assessment of fractional drug removal by extra-corporeal dialysis. Biopharmaceutics and Drug Disposition 3: 165–173 (1982).CrossRefGoogle Scholar
  86. Lee, P.; Crutch, E.R. and Morrison, R.B.I.: Doxycycline: studies in normal subjects and patients with renal failure. New Zealand Medical Journal 75: 355–358 (1972).PubMedGoogle Scholar
  87. Lee, C.S.; Marbury, T.C.; Perrin, J.H. and Fuller, J.J.: Hemodialysis of theophylline in uremic patients. Journal of Clinical Pharmacology 19: 219–226 (1979).PubMedGoogle Scholar
  88. Lec, C.S.; Bruni, J.; Marbury, T.C.; Perchalski, R.J. and Wang, L.H.: Hemodialysis and total body elimination of carbamaz-epine during chronic hemodialysis. Clinical Toxicology 17: 429–438 (1980a).CrossRefGoogle Scholar
  89. Lcc, C.S.; Marbury, T.C. and Benet, L.Z.: Clearance calculations in hemodialysis: Application to blood, plasma and dialysate measurements for ethambutol. Journal of Pharmacokinetics and Biopharmaceutics 8: 65–81 (1980b).Google Scholar
  90. Lcc, C.S.; Marbury, T.C; Wang, L.H. and Cade, R.J.: Hemodialysis for acetaminophen detoxification. Clinical Toxicology 18: 431–439 (1981a).CrossRefGoogle Scholar
  91. Lee, C.S.; Wang, L.H.; Majeske, B.L. and Marbury, T.C.: Phar-macokinetics of dyphylline elimination by uremic patients. Journal of Pharmacology and Experimental Therapeutics 217: 340–344 (1981b).PubMedGoogle Scholar
  92. Lee, C.S.; Marbury, T.C.; Perchalski, R.T. and Wilder, B.J.: Phar-macokinetics of primidone elimination by uremic patients. Journal of Clinical Pharmacology 22: 301–308 (1982).PubMedCrossRefGoogle Scholar
  93. Lee, C.S.; Paterson, J. and Marbury, T.C.: Comparative Phar-macokinetics of theophylline in hemodialysis and peritoneal dialysis. Journal of Clinical Pharmacology 23: 274–280 (1983).PubMedGoogle Scholar
  94. Leroy, A.; Humbert, G. and Fillastre, J.P.: Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrobial Agents and Chemotherapy 19: 965–971 (1981).PubMedCrossRefGoogle Scholar
  95. Letourneau-Saheb, I.; Lapierre, L. and Daigneault, R.: Gentamycin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure. International Journal of Clinical Pharmacology and Biopharmaceutics 15: 116–121 (1977).Google Scholar
  96. Lelteri, J.M.; Miraflor, F.; Tablante, V. and Siddigi, S.: Doxycycline (Vibramycin®) in chronic renal failure. Nephron 11: 318–324 (1973).CrossRefGoogle Scholar
  97. Levy, G.: Pharmacokinetics in renal disease. American Journal of Medicine 62: 461–465 (1977).PubMedCrossRefGoogle Scholar
  98. Levy, G.; Gibson, J.P.; Whitman, W. and Procknal, J.: Hemodialysis clearance of theophylline. Journal of the American Medical Association 237: 1466–1467 (1977).PubMedCrossRefGoogle Scholar
  99. Lewi, P.J.; Boelaert, J.; Daniels, R.; De Meyere, R.; Van Landuvt, H. and Heykants, J.J.P.: Pharmacokinetic profile of intravenous miconazole in man. European Journal of Clinical Pharmacology 10: 49–54 (1976).CrossRefGoogle Scholar
  100. Lowenthal, D.T.; Briggs, W.A; Gibson, T.P.; Nelson, H. and Cirksena, W.J.: Pharmacokinetics of oral propranolol in chronic renal disease. Clinical Pharmacology and Therapeutics 16: 761–769 (1974).PubMedGoogle Scholar
  101. Ma, K.W.; Brown, D.C.; Masler, D.S. and Silvis, S.E.: Effects of renal failure on blood levels of cimetidine. Gastroenterology 74: 473–477 (1978).PubMedGoogle Scholar
  102. Maddock, R.K. and Bloomer, H.A.: Meprobamate overdose: evaluation of its severity and methods of treatment. Journal of the American Medical Association 201: 999–1003 (1967).PubMedCrossRefGoogle Scholar
  103. Marbury, T.C.; Lee, C.S.; Burni, J. and Wilder, B.J.: The pharmacokinetics of valproic acid in patients with chronic renal failure during hemodialysis. Dialysis and Transplantation 9: 961–964 (1980a).Google Scholar
  104. Marbury, T.C.; Wang, L.H. and Lee, C.S.: Hemodialysis of acetaminophen in uremic patients. International Journal of Artificial Organs 5: 263–266 (1980b).Google Scholar
  105. Marbury, T.C.; Lee, C.S.; Perchalski, R.J. and Wilder, B.J.: Hemodialysis clearance of ethosuximide in end-stage renal disease patients. American Journal of Hospital Pharmacy 38: 1757–1760 (1981).PubMedGoogle Scholar
  106. Marbury, T.C.; Sheppard, J.E.; Gibbons, K. and Lee, C.S.: Combined antidotal and hemodialysis treatments for nitroprusside-induced cyanide toxicity. Journal of Toxicology — Clinical Toxicology 19: 475–482 (1982).PubMedCrossRefGoogle Scholar
  107. Mauer, S.M.; Paxson, C.L.; Von Hartizsch, B.; Buselmeier, T.J. and Kjellstrand, C.J.: Hemodialysis in an infant with pro-poxyphene intoxication. Clinical Pharmacology and Therapeutics 17: 88–92 (1975).PubMedGoogle Scholar
  108. McCloskey, R.V.; Terry, E.E.; McCracken, A.W.; Sweeney, M.J. and Forland, M.F.: Effects of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium. Antimicrobial Agents and Chemotherapy 1: 90–93 (1972).PubMedCrossRefGoogle Scholar
  109. Murray, T.G.; Chiang, S.T.; Koepke, H.H. and Walker, B.R.: Renal disease, age and oxazepam kinetics. Clinical Pharmacology and Therapeutics 30: 805–809 (1981).PubMedCrossRefGoogle Scholar
  110. Nauta, E.H. and Manie, H.: Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clinical Pharmacology and Therapeutics 20: 98–108 (1976).PubMedGoogle Scholar
  111. Nauta, E.H.; Mattie, H. and Goslings, W.R.D.: Pharmacokinetics of cloxacillin in patients on chronic intermittent haemodialy-sisand in healthy subjects. Chemotherapy 19: 261–271 (1973).PubMedCrossRefGoogle Scholar
  112. Nieto, M.J.; Lanao, J.M.; Dominguez-Gil, A.; Tabernero, J.M. and Macias, J.F.: Elimination of cefroxadine from patients undergoing dialysis. European Journal of Clinical Pharmacology 24: 109–112 (1983).PubMedCrossRefGoogle Scholar
  113. Odar-Cederlof, I. and Borgâ, O.: Kinetics of diphenylhydantoin in uremic patients: Consequences of decreased plasma protein binding. European Journal of Clinical Pharmacology 7: 31–37 (1974).PubMedCrossRefGoogle Scholar
  114. Pahl, M.V. and Vaziri, N.D.: In-vivo and in-vitro hemodialysis studies of thiocyanate. Journal of Toxicology: Clinical Toxicology 19: 965–974 (1982).PubMedCrossRefGoogle Scholar
  115. Parry, M.F. and Neu, H.C.: Pharmacokinetics of ticarcillin in patients with abnormal renal function. Journal of Infectious Diseases 133: 46–49 (1976).PubMedCrossRefGoogle Scholar
  116. Pechere, J.C. and Dugal, R.: Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renalimpaired hemodialyzed patients. Journal of Infectious Diseases 134 (Suppl.): 5118–5124 (1976).CrossRefGoogle Scholar
  117. Pechere, J. and Dugal, R.: Clinical pharmacokinetics of amino-glycosides. Clinical Pharmacokinetics 4: 170–199 (1979).PubMedCrossRefGoogle Scholar
  118. Ponstal, P.G.; Bismuth, C; Baud, F. and Galliot, M.: Respective roles of gastric lavage, hemodialysis, hemoperfusion, diuresis, and hepatic metabolism in the elimination of a massive meprobamate overdose. Nouvelle Presse Médicale 11: 1557–1558 (1982).Google Scholar
  119. Randall, R.E.; Singh, R.; Laster, J.; Belle, C. and Setter, J.G.: Increased intracranial pressure from unsustained levels of plasma mannitol during hemodialysis. Journal of Laboratory and Clinical Medicine 70: 129–137 (1967).PubMedGoogle Scholar
  120. Rcgeur, L.; Colding, H.; Jensen, H. and Kampmann, J.P.: Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy 11: 214–218 (1977).CrossRefGoogle Scholar
  121. Reidenberg, M.M.: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. American Journal of Medicine 62: 466–469 (1977a).PubMedCrossRefGoogle Scholar
  122. Reidenberg, M.M.: The biotransformation of drugs in renal failure. American Journal of Medicine 62: 482–485 (1977b).PubMedCrossRefGoogle Scholar
  123. Reinarz, J.A. and Mclntosh, D.A.: Lincomycin excretion in patients with normal renal function, severe azotemia and with hemodialysis and peritoneal dialysis. Antimicrobial Agents and Chemotherapy 5: 232–244 (1965).PubMedGoogle Scholar
  124. Reisberg, B.E. and Mandelbaum, J.M.: Cephalexin: absorption and excretion as related to renal function and hemodialysis. Infection and Immunity 3: 540–543 (1971).PubMedGoogle Scholar
  125. Reuning, R.H.; Sams, R.A. and Notari, R.E.: Role of pharmaco-kinetics in drug dosage adjustment: Pharmacologic effect, kinetics and apparent volume of distribution of digoxin. Journal of Clinical Pharmacology 13: 127–141 (1973).Google Scholar
  126. Richens, A.: Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics 4: 153–169 (1979).PubMedCrossRefGoogle Scholar
  127. Riva, E.; Fossali, E. and Bettinelli, A.: Kinetics of furosemide in children with chronic renal failure undergoing regular hemodialysis. European Journal of Clinical Pharmacology 21: 303–306 (1982).PubMedCrossRefGoogle Scholar
  128. Roberts, A.; Eastwood, T.; Gower, P.; Fenton, C.M. and Curtis, JR.: Serum and plasma concentrations of clindamycin following a single intra-muscular injection of clindamycin phosphate in maintenance hemodialysis patients and normal subjects. European Journal of Clinical Pharmacology 14: 435–439 (1978).PubMedCrossRefGoogle Scholar
  129. Rodrigo, F.; Shideman, J.; McHugh, R.; Buselmeier, T. and Kjellstrand, C: Osmolality changes during hemodialysis. Annals of Internal Medicine 86: 554–561 (1977).PubMedGoogle Scholar
  130. Rosenbaum, J.L.; Winsten, S.; Kramer, M.S.; Moros, J. and Raja, R.: Resin hemoperfusion in the treatment of drug intoxification. Transactions of the American Society for Artificial Internal Organs 16: 134–140 (1970).PubMedGoogle Scholar
  131. Rudnick, M.; Morrison, G.; Walker, B. and Singer, I.: Renal failure, hemodialysis and nafcillin kinetics. Clinical Pharmacology and Therapeutics 20: 413–423 (1976).PubMedGoogle Scholar
  132. Rustein, D.D.; Catelli, W.P. and Nickerson, R.J.: Heparin and human lipid metabolism. Lancet 1: 1003–1008 (1969).CrossRefGoogle Scholar
  133. Schmidt, P.; Korn, A.; Hitzenberger, G.; Zazgornik, J. and Kopsa, H.: Pharmacokinetics of trimethoprim and sulfametrol in patients with end stage renal failure and hemodialysis treatment. Wiener Medizinische Wochenschrift 130: 171–173 (1980).PubMedGoogle Scholar
  134. Schusziarra, V.; Ziekursch, V.; Schlamp, R. and Siemensen, H.C.: Pharmacokinetics of azathioprine under hemodialysis. International Journal of Clinical Pharmacology and Biopharmacy 14: 298–302 (1976).PubMedGoogle Scholar
  135. Senekjian, H.O.; Lee, C.S.; Kuo, T.H.; Au, D.S. and Krothapalli, R.: Absorption and disposition of ibuprofen in hemodialyzed urcmic patients. European Journal of Rheumatology and Inflammation. (In press, 1983).Google Scholar
  136. Setter, J.G.; Mäher, J.F. and Schreiner, G.E.: Barbiturate intoxication. Archives of Internal Medicine 117: 224–236 (1966).PubMedCrossRefGoogle Scholar
  137. Sherlock, J.E. and Letteri, J.M.: Effect of hemodialysis on methylprednisolone plasma levels. Nephron 18: 208–211 (1977).PubMedCrossRefGoogle Scholar
  138. Skoutakis, V.A.; Acchiardo, S.R.; Meyer, M.C. and Hatch, F.E.: Folic acid dosage for chronic hemodialysis patient. Clinical Pharmacology and Therapeutics 18: 200–204 (1975).PubMedGoogle Scholar
  139. Slaughter, R.L.; Cerra, F.B. and Koup, J.R.: Effect of hemodialysis on total body clearance of chloramphenicol. American Journal of Hospital Pharmacy 37: 1083–1086 (1980).PubMedGoogle Scholar
  140. Spyker, D.A.; Gober, L.L.; Scheid, W.M.; Sande, M.A. and Bolton, W.K.: Pharmacokinetics of cefaclor in renal failure: Effects of multiple doses and hemodialysis. Antimicrobial Agents and Chemotherapy 21: 278–281 (1982).PubMedCrossRefGoogle Scholar
  141. Stec, G.P.; Atkinson, A.J.; Nevin, M.J.; Thenot, J.P.; Ruo, T.I.; Gibson, T.P.; Ivanovich, P. and Greco, F.: N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clinical Pharmacology and Therapeutics 26: 618–627 (1979).PubMedGoogle Scholar
  142. Sullivan, J.F. and Eisenstein, A.B.: Ascorbic acid depletion in patients undergoing chronic hemodialysis. American Journal of Clinical Nutrition 23: 1339–1346 (1970).PubMedGoogle Scholar
  143. Takki, S.; Gambertoglio, J.G.; Honda, D.H. and Tozer, T.N.: Pharmacokinetic evaluation of hemodialysis in acute drug overdose. Journal of Pharmacokinetics and Biopharmaceutics 6: 427–442 (1978).PubMedCrossRefGoogle Scholar
  144. Tilstone, W.J.; Winchester, J.F. and Reavery, P.C.: The use of pharmacokinetic principles in determining the effectiveness of removal of toxins from blood. Clinical Pharmacokinetics 4: 23–37 (1979).PubMedCrossRefGoogle Scholar
  145. Tjandramaga, T.B.; Thomas, J.; Verbeeck, R.; Verberckmoes, R. and De Schepper, P.J.: The effect of end-stage renal failure and hemodialysis on the elimination kinetics of sotaolol. British Journal of Clinical Pharmacology 3: 259–265 (1976).PubMedCrossRefGoogle Scholar
  146. Tozer, T.N.; Witt, L.D.; Gee, L.; Tong, T.G. and Gambertoglio, J.G.: Evaluation of hemodialysis for ethchlorvynol overdose. American Journal of Hospital Pharmacy 31: 986–989 (1974).PubMedGoogle Scholar
  147. Vaziri, N.D.; Ness, R.L. and Barton, C.H.: Hemodialysis clearance of cimetidine. Archives of Internal Medicine 138: 1685–1686 (1978).PubMedCrossRefGoogle Scholar
  148. Vaziri, N.D.; Saiki, J.K. and Hughes, W.: Clearance of lidocaine by hemodialysis. Southern Medical Journal 72: 1567–1568 (1979).PubMedCrossRefGoogle Scholar
  149. Venuto, R.C. and Plaut, M.: Cephalothin handling in patients undergoing hemodialysis. Antimicrobial Agents and Chemotherapy 10: 50–52 (1970).PubMedGoogle Scholar
  150. Wang, L.H.; Lee, C.S. and Marbury, T.C.: Hemodialysis of mefenamic acid in uremia. American Journal of Hospital Pharmacy 37: 956–958 (1980).PubMedGoogle Scholar
  151. Wang, L.H.; Lee, C.S.; Majeske, B.L. and Marbury, T.C.: Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cell, and dialystate measurements for cyclophosphamide. Clinical Pharmacology and Therapeutics 29: 365–372 (1981).PubMedCrossRefGoogle Scholar
  152. Watanabe, A.S.: Pharmacokinetic aspects of the dialysis of drugs. Drug Intelligence and Clinical Pharmacy. 11: 407–416 (1977).Google Scholar
  153. Woie, L. and Oyri, A.: Quinidine intoxication treated with hemodialysis. Acta Medica Scandinavica 195: 237–239 (1974).PubMedCrossRefGoogle Scholar
  154. Wood, A.J.; Vestal, R.E.; Spannuth, C.L.; Stone, W.J.; Wilkinson, G.R. and Shand, D.G.: Propranolol disposition in renal failure. British Journal of Clinical Pharmacology 10: 561–566 (1980).PubMedCrossRefGoogle Scholar
  155. Wu, M.J.; Ing, T.S.; Soung, L.S.; Daugirdas, J.T.; Hano, J.E. and Gandhi, V.C.: Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clinical Nephrology 17: 19–23 (1982).PubMedGoogle Scholar
  156. Ych, B.K.; Dayton, P.G. and Waters, W.C. III.: Removal of alpha methyldopa (Aldomet) in man by dialysis. Proceedings of the Society for Experimental Biology and Medicine 135: 840–843 (1970).Google Scholar

Copyright information

© ADIS Press Limited 1984

Authors and Affiliations

  • Ching-san C. Lee
    • 1
    • 2
  • Thomas C. Marbury
    • 1
    • 2
  1. 1.Department of PharmaceuticsUniversity of Houston at Texas Medical CenterHoustonUSA
  2. 2.Department of Internal MedicineOrlando Regional Medical CenterOrlandoUSA

Personalised recommendations